UMIN-CTR Clinical Trial

Recruitment status Preinitiation
Unique ID issued by UMIN UMIN000038420
Receipt No. R000043781
Scientific Title Effect of high-frequency rTMS on patients with leg paralysis
Date of disclosure of the study information 2021/07/07
Last modified on 2019/10/29 (Ver. 1)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Effect of high-frequency rTMS on patients with leg paralysis
Acronym Effect of high-frequency rTMS on patients with leg paralysis
Scientific Title Effect of high-frequency rTMS on patients with leg paralysis
Scientific Title:Acronym Effect of high-frequency rTMS on patients with leg paralysis
Region
Japan

Condition
Condition Stroke
Classification by specialty
Rehabilitation medicine
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 Verification of the effects of high frequency repetitive transcranial magnetic stimulation on lower limb paralysis in stroke patients
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Brunnstrom recovery stage
Fugl-Meyer assessment
Modified Ashworth Scale
Functional Reach Test
Timed Up and Go test
10m gait
Functional balance scale
BESTEST
Functional Ambulation Categories
Functional Independence Measure
Key secondary outcomes

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Device,equipment
Interventions/Control_1 High-frequency repetitive transcranial magnetic stimulation on lower limb area
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
70 years-old >=
Gender Male and Female
Key inclusion criteria The lesion does not extend to the cerebral cortex

In the case of cerebral hemorrhage after 0 days after onset, hematoma is absorbed

10m walk is possible by walking alone (balance ability is not included. Contact assistance is also possible)

No history of epilepsy or seizures

Metals close to the stimulation site (stimulators such as cochlear implants, magnetic clips, deep brain stimulation and vagus nerve stimulation), without a cardiac pacemaker

Intracranial titanium products, or magnetically mounted dentures, without implants
Intracranial lesions at risk for seizures
There is no

Those who have not taken medications that lower the seizure threshold (such as tricyclic antidepressants, maprotiline, theophylline, methylphenidate, ketamine, clozapine, zotepine).

Those who are not complicated by serious physical illness during pregnancy, abuse, withdrawal of alcohol, caffeine or stimulant.

Those who do not have cognitive decline or higher brain damage that may affect or be dangerous in the intervention of this study
Key exclusion criteria The lesion does not extend to the cerebral cortex

In the case of cerebral hemorrhage after 0 days after onset, hematoma is absorbed

10m walk is possible by walking alone (balance ability is not included. Contact assistance is also possible)

No history of epilepsy or seizures

Metals close to the stimulation site (stimulators such as cochlear implants, magnetic clips, deep brain stimulation and vagus nerve stimulation), without a cardiac pacemaker

Intracranial titanium products, or magnetically mounted dentures, without implants
Intracranial lesions at risk for seizures
There is no

Those who have not taken medications that lower the seizure threshold (such as tricyclic antidepressants, maprotiline, theophylline, methylphenidate, ketamine, clozapine, zotepine).

Those who are not complicated by serious physical illness during pregnancy, abuse, withdrawal of alcohol, caffeine or stimulant.

Those who do not have cognitive decline or higher brain damage that may affect or be dangerous in the intervention of this study
Target sample size 10

Research contact person
Name of lead principal investigator
1st name Yoshiyuki
Middle name
Last name Sakoda
Organization Medical Corporation Motoyama rehabilitation
Hospital
Division name rehabilitation
Zip code 6580015
Address 7-7-15 motoyamaminami-cho,hidgashinada-ku kobe-shi hyogo-ken
TEL 0784128080
Email sako19920707@gmail.com

Public contact
Name of contact person
1st name Yoshiyuki
Middle name
Last name Sakoda
Organization Motoyama Rehabilitation Hospital
Division name rehabilitation
Zip code 6580015
Address 7-7-15 motoyamaminami-cho,hidgashinada-ku kobe-shi hyogo-ken
TEL 0784128080
Homepage URL
Email sako19920707@gmail.com

Sponsor
Institute Motoyama Rehabilitation Hospital
Institute
Department

Funding Source
Organization Motoyama Rehabilitation Hospital
Organization
Division
Category of Funding Organization Other
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Motoyama Rehabilitation Hospital
Address 7-7-15 motoyamaminami-cho,hidgashinada-ku kobe-shi hyogo-ken
Tel 0784128080
Email sako19920707@gmail.com

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2021 Year 07 Month 07 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Preinitiation
Date of protocol fixation
2019 Year 11 Month 11 Day
Date of IRB
Anticipated trial start date
2019 Year 11 Month 20 Day
Last follow-up date
2021 Year 11 Month 20 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2019 Year 10 Month 29 Day
Last modified on
2019 Year 10 Month 29 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043781